Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Entropy Technologies LP

Entropy Technologies LP raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 20.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,700 shares of the life sciences company’s stock after purchasing an additional 2,137 shares during the quarter. Entropy Technologies LP’s holdings in Illumina were worth $1,697,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cetera Investment Advisers grew its position in shares of Illumina by 25.8% during the second quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock worth $1,919,000 after buying an additional 3,767 shares in the last quarter. CWM LLC grew its holdings in Illumina by 179.8% during the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock worth $2,114,000 after acquiring an additional 10,414 shares in the last quarter. UMB Bank n.a. increased its position in shares of Illumina by 23.7% in the 3rd quarter. UMB Bank n.a. now owns 1,659 shares of the life sciences company’s stock worth $216,000 after purchasing an additional 318 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Illumina by 323.9% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,047 shares of the life sciences company’s stock valued at $136,000 after purchasing an additional 800 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in shares of Illumina during the third quarter worth about $276,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Down 9.6 %

Illumina stock opened at $111.06 on Monday. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The stock has a market cap of $17.61 billion, a price-to-earnings ratio of -14.46 and a beta of 1.10. The company’s 50-day moving average price is $136.70 and its two-hundred day moving average price is $135.43. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, analysts expect that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Guggenheim lowered their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday. Stephens upped their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Finally, TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and reduced their price target for the stock from $177.00 to $140.00 in a research report on Friday. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average target price of $161.40.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.